Xencor (NASDAQ: XNCR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.600 | 0.390 | 0.9900 | ||||
REV | 25.730M | 85.495M | 59.765M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Xencor (NASDAQ: XNCR) through any online brokerage.
Other companies in Xencor’s space includes: Valneva (NASDAQ:VALN), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA), CareDx (NASDAQ:CDNA) and Ligand Pharmaceuticals (NASDAQ:LGND).
The latest price target for Xencor (NASDAQ: XNCR) was reported by Piper Sandler on Monday, May 23, 2022. The analyst firm set a price target for 42.00 expecting XNCR to rise to within 12 months (a possible 54.87% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Xencor (NASDAQ: XNCR) is $27.12 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Xencor.
Xencor’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Xencor.
Xencor is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.